XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Supplementary Balance Sheet Information
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplementary Balance Sheet Information

4. Supplementary Balance Sheet Information

Investments available for sale

Investments available for sale consisted of the following:

 

 

As of September 30, 2024

 

(in thousands)

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Market Value

 

Maturity less than 1 year:

 

 

 

 

 

 

 

 

 

 

 

 

Certificate of deposit

 

$

334

 

 

$

—

 

 

$

—

 

 

$

334

 

Corporate debt securities

 

 

16,213

 

 

 

36

 

 

 

(2

)

 

 

16,247

 

Commercial paper

 

 

308

 

 

 

2

 

 

 

—

 

 

 

310

 

U.S. treasury securities

 

 

18,896

 

 

 

8

 

 

 

(10

)

 

 

18,894

 

Total maturity less than 1 year

 

 

35,751

 

 

 

46

 

 

 

(12

)

 

 

35,785

 

Maturity 1 to 2 years:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

8,796

 

 

 

49

 

 

 

(1

)

 

 

8,844

 

Total maturity 1 to 2 years

 

 

8,796

 

 

 

49

 

 

 

(1

)

 

 

8,844

 

 

 

 

 

 

 

 

 

 

 

 

 

Total short-term investments

 

$

44,547

 

 

$

95

 

 

$

(13

)

 

$

44,629

 

 

 

 

As of December 31, 2023

 

(in thousands)

 

Amortized Cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Losses

 

 

Fair Market Value

 

Maturity less than 1 year:

 

 

 

 

 

 

 

 

 

 

 

 

Certificate of deposit

 

$

8,317

 

 

$

16

 

 

$

—

 

 

$

8,333

 

Corporate debt securities

 

 

10,948

 

 

 

8

 

 

 

(16

)

 

 

10,940

 

Commercial paper

 

 

6,193

 

 

 

9

 

 

 

—

 

 

 

6,202

 

U.S. government agencies

 

 

835

 

 

 

—

 

 

 

(1

)

 

 

834

 

Total maturity less than 1 year

 

 

26,293

 

 

 

33

 

 

 

(17

)

 

 

26,309

 

Maturity 1 to 2 years:

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

8,437

 

 

 

6

 

 

 

(10

)

 

 

8,433

 

U.S. treasury securities

 

 

18,505

 

 

 

—

 

 

 

(79

)

 

 

18,426

 

Total maturity 1 to 2 years

 

 

26,942

 

 

 

6

 

 

 

(89

)

 

 

26,859

 

 

 

 

 

 

 

 

 

 

 

 

 

Total short-term investments

 

$

53,235

 

 

$

39

 

 

$

(106

)

 

$

53,168

 

 

We periodically review our portfolio of debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For debt securities where the fair value of the investment is less than the amortized cost basis, we have assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses in investments available for sale debt securities at September 30, 2024, were substantially due to changes in interest rates, not due to increased credit risks associated with specific securities. Accordingly, we have not recorded an allowance for credit losses. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consisted of the following:

 

 

As of September 30, 2024

 

(in thousands)

 

Fair Market Value

 

 

Gross Unrealized Loss

 

Total

 

$

—

 

 

$

—

 

 

 

As of December 31, 2023

 

(in thousands)

 

Fair Market Value

 

 

Gross Unrealized Loss

 

Corporate debt securities

 

$

397

 

 

$

(3

)

 

Property and equipment

Property and equipment consisted of the following:

 

(in thousands)

 

As of September 30,
2024

 

 

As of December 31,
2023

 

Furniture and office equipment

 

$

1,067

 

 

$

1,067

 

Leasehold improvements

 

 

2,568

 

 

 

2,568

 

Laboratory equipment

 

 

1,414

 

 

 

1,355

 

Property and equipment, gross

 

 

5,049

 

 

 

4,990

 

Less—accumulated depreciation and amortization

 

 

(4,056

)

 

 

(3,752

)

Property and equipment, net

 

$

993

 

 

$

1,238

 

 

Accrued Liabilities

Accrued liabilities consisted of the following:

 

(in thousands)

 

As of September 30,
2024

 

 

As of December 31,
2023

 

Clinical trials

 

$

4,271

 

 

$

4,309

 

Accrued compensation

 

 

1,993

 

 

 

2,737

 

Research agreements and services

 

 

637

 

 

 

530

 

Other accrued liabilities

 

 

274

 

 

 

207

 

Total accrued liabilities

 

$

7,175

 

 

$

7,783